AA
RPRX icon

ALPS Advisors’s Royalty Pharma RPRX Stock Holding History

ALPS Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.7M Sell
315,335
-181,347
-37% -$9.44M 0.08% 140
2026
Q1 		$23.8M Sell
496,682
-24,101
-5% -$1.06M 0.11% 118
2025
Q4 		$20.1M Sell
520,783
-32,341
-6% -$1.23M 0.12% 125
2025
Q3 		$19.5M Buy
+553,124
New +$20M 0.11% 134
2024
Q3 		– Sell
-11,488
Closed -$303K – 1114
2024
Q2 		$303K Sell
11,488
-62
-0.5% -$1.72K ﹤0.01% 841
2024
Q1 		$351K Buy
+11,550
New +$340K ﹤0.01% 832
2021
Q3 		– Sell
-7,232
Closed -$296K – 1005
2021
Q2 		$296K Hold
7,232
– – ﹤0.01% 839
2021
Q1 		$315K Buy
+7,232
New +$343K ﹤0.01% 796

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ALPS Advisors's RPRX Position: Q2 2026 in Review

ALPS Advisors reduced its Royalty Pharma (RPRX) stake by 37% in Q2 2026, selling an estimated $9.44M and leaving 315,335 shares worth $17.7M. The position accounts for 0.08% of the portfolio, ranked #140.

ALPS Advisors first reported a position in RPRX in Q1 2021 and has held it in 8 quarters since. The position peaked at $23.8M in Q1 2026. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • ALPS Advisors held 315,335 shares of Royalty Pharma worth $17.7M as of Q2 2026.
  • ALPS Advisors sold 181,347 Royalty Pharma shares in Q2 2026, an estimated $9.44M.
  • Royalty Pharma made up 0.08% of ALPS Advisors's portfolio in Q2 2026, its #140 holding.
  • ALPS Advisors first reported a position in Royalty Pharma in Q1 2021 and has held it in 8 quarters since.
  • ALPS Advisors's Royalty Pharma position peaked at $23.8M in Q1 2026.
  • 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.